Highly accurate results; noninvasive sampling; rapid turnaround time; breakthrough technology;
Tests greater than 98% Sensitivity; Sampling: Liquid biopsy (cancer), Saliva (Infectious diseases)
RAPID VIRAL DETECTION SYSTEMS (RVDS)
See us at Hospitalar 2025 · Booth: E-310G
RVDS and InteGen, both founded by Dr. Babu are affiliated companies that have a track record of developing innovative, rapid, noninvasive diagnostic tests. RVDS focuses on infectious diseases while InteGen concentrates on early cancer detection and prenatal genetic testing.
Orlando, Florida (FL), United States
Healthcare
Products & Services
Ultra-fast cell-based Noninvasive Prenatal Diagnosis (cb-NIPD)
Rapid Viral Detection Systems (RVDS)
SAMPLE SOURCE Peripheral Blood
TARGET TISSUE Circulating fetal nucleated red blood cells (fnRBC) & trophoblasts
GENETIC PROFILING Chromosome ploidy and common microdeletions by InstaFISH
SUITABLE FOR All pregnancies (high- and low-risk) after 6 weeks gestation
ASSAY TURNAROUND 3 hours
TIME
TARGET TISSUE Circulating fetal nucleated red blood cells (fnRBC) & trophoblasts
GENETIC PROFILING Chromosome ploidy and common microdeletions by InstaFISH
SUITABLE FOR All pregnancies (high- and low-risk) after 6 weeks gestation
ASSAY TURNAROUND 3 hours
TIME
Instant detection of infectious diseases by Ion Mobility Spectrometry
Rapid Viral Detection Systems (RVDS)
Rapid Test results in 23 seconds
Accurate Highly sensitive detection
Easy Operation Meant for Layperson use
Point of Care Easily portable device
Non-invasive Saliva-based swab under the tongue
Reliable > 99% sensitivity and Specificity
Accurate Highly sensitive detection
Easy Operation Meant for Layperson use
Point of Care Easily portable device
Non-invasive Saliva-based swab under the tongue
Reliable > 99% sensitivity and Specificity
Ultra-fast selection of genetically normal embryos for In vitro fertilization (IVF)
Rapid Viral Detection Systems (RVDS)
SAMPLE SOURCE. Isolated Trophoblasts
TARGET TISSUE All 24 chromosomes
GENETIC PROFILING Chromosome ploidy and common microdeletions
SUITABLE FOR Fresh and/or Frozen embryo transfer
ASSAY TURNAROUND TIME 3 hours
TARGET TISSUE All 24 chromosomes
GENETIC PROFILING Chromosome ploidy and common microdeletions
SUITABLE FOR Fresh and/or Frozen embryo transfer
ASSAY TURNAROUND TIME 3 hours
Ultra-Fast detection of all Human Cancers using Non-Invasive liquid biopsy
Rapid Viral Detection Systems (RVDS)
SAMPLE SOURCE Plasma-based Peripheral Blood
TARGET ORGANELLE Oncosome (a medium sized extracellular vesicle; EV)
CANCER DETECTION Enumeration (cut-off based) and molecular characterization (abnormal
DNA ploidy) of Oncosomes
CANCER CLASSIFICATION Cell surface immunofluorescence profiling
ASSAY TURNAROUND TIME 2 hours
TARGET ORGANELLE Oncosome (a medium sized extracellular vesicle; EV)
CANCER DETECTION Enumeration (cut-off based) and molecular characterization (abnormal
DNA ploidy) of Oncosomes
CANCER CLASSIFICATION Cell surface immunofluorescence profiling
ASSAY TURNAROUND TIME 2 hours
Connect with us at
About
Rapid Viral Diagnostic Systems (RVDS) is a biotechnology InteGen-affiliated company with a focus on and a track record of developing innovative tools. It has developed proprietary, clinically validated technologies (Ion Mobility Spectrometry) which allow for the rapid detection (23 seconds) and diagnosis of several infectious and tropical diseases to meet the unmet need for instantaneous point-of-care (POC) testing and diagnosis. The patent-pending tests will revolutionize POC diagnostics by offering a cost effective, noninvasive (saliva based), and highly accurate test without the need for physician administration. Currently RVDS’ rapid test, ViralStatDx TM can detect malaria, TB, hepatitis, HIV/AIDS, COVID-19, flu and RSV 60 times faster than traditional methods. Research is ongoing to expand the test portfolio to include additional infectious and non-infectious diseases.
InteGen is a diagnostic reagent manufacturing company that has developed disruptive technologies, including innovative DNA probes with clinical applications in cancer genetics, prenatal diagnoses, miscarriages, and IVF. InteGen’s InstaFish technology provides results of up to 10 targets in a single assay in less than1 hour, using our extremely cost-effective multi-color and multiplex probe design. Our newest product, OncoSureTM can detect all human cancers in less than 2 hours using a non-invasive 3cc peripheral blood sample. It uses powerful screening technology that can detect cancers much earlier and faster than expensive and invasive serum marker and imaging tests (e.g. PSA, CT, and PET scan). OncoSureTM can also monitor cancer treatment efficacy in 100% concordance with clinical remission. The test has the following characteristics: Sensitivity (96.88%), Specificity. (92.31%), Positive Predictive Value (81.58%), Negative Predictive Value (98.82%) and Accuracy/Area Under the Curve (AUC 0.944).
All DNA probes are manufactured in our Orlando facility which is FDA compliant with quality system 21CFR820 and cGMP. Our FDA registration number is #3011310310
To learn more, visit our Booth: USA Partnership Pavilion E-310G
InteGen is a diagnostic reagent manufacturing company that has developed disruptive technologies, including innovative DNA probes with clinical applications in cancer genetics, prenatal diagnoses, miscarriages, and IVF. InteGen’s InstaFish technology provides results of up to 10 targets in a single assay in less than1 hour, using our extremely cost-effective multi-color and multiplex probe design. Our newest product, OncoSureTM can detect all human cancers in less than 2 hours using a non-invasive 3cc peripheral blood sample. It uses powerful screening technology that can detect cancers much earlier and faster than expensive and invasive serum marker and imaging tests (e.g. PSA, CT, and PET scan). OncoSureTM can also monitor cancer treatment efficacy in 100% concordance with clinical remission. The test has the following characteristics: Sensitivity (96.88%), Specificity. (92.31%), Positive Predictive Value (81.58%), Negative Predictive Value (98.82%) and Accuracy/Area Under the Curve (AUC 0.944).
All DNA probes are manufactured in our Orlando facility which is FDA compliant with quality system 21CFR820 and cGMP. Our FDA registration number is #3011310310
To learn more, visit our Booth: USA Partnership Pavilion E-310G
